Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

GRTX

Galera Therapeutics Inc

Jun 17 • 10:08AM ET

0.0933

Dollar change -0.0007
Percentage change -0.74	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.91	Insider Own	36.15%	Shs Outstand	54.39M	Perf Week	-5.47%
Market Cap	5.07M	Forward P/E	-	EPS next Y	-	Insider Trans	4.98%	Shs Float	36.24M	Perf Month	-52.23%
Income	-	PEG	-	EPS next Q	-	Inst Own	18.96%	Short Float	5.86%	Perf Quarter	-61.49%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	1.17	Perf Half Y	-31.70%
Book/sh	-2.48	P/B	-	EPS next Y	-	ROA	-	Short Interest	2.12M	Perf Year	-97.25%
Cash/sh	-	P/C	-	EPS next 5Y	34.40%	ROE	-	52W Range	0.09 - 3.41	Perf YTD	-35.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-97.26%	Beta	1.97
Dividend TTM	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	9.38%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	-	EPS Y/Y TTM	55.14%	Oper. Margin	-	RSI (14)	29.85	Volatility	15.94% 14.87%
Employees	7	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	-
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.01	Prev Close	0.09
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	1.82M	Price	0.09
SMA20	-38.98%	SMA50	-44.69%	SMA200	-46.88%	Trades		Volume	3,866	Change	-0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-23	Downgrade	Piper Sandler	Overweight → Neutral	$6 → $0.50
Oct-19-21	Downgrade	BTIG Research	Buy → Neutral
Oct-19-21	Downgrade	BofA Securities	Buy → Underperform	$17 → $2
Apr-26-21	Resumed	Credit Suisse	Outperform	$15
Dec-16-20	Upgrade	Credit Suisse	Neutral → Outperform	$9 → $15
Dec-07-20	Initiated	H.C. Wainwright	Buy	$15
Dec-02-19	Initiated	Credit Suisse	Neutral
Dec-02-19	Initiated	Citigroup	Buy
Dec-02-19	Initiated	BTIG Research	Buy
Dec-02-19	Initiated	BofA/Merrill	Buy

May-13-24 02:53PM	GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-03-24 07:00AM	Galera Adopts Limited Duration Stockholder Rights Agreement (GlobeNewswire)
Mar-28-24 11:53AM	GRTX Stock Earnings: Galera Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -8.79%
07:00AM	Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates (GlobeNewswire)
07:00AM	Loading…
Nov-14-23 07:00AM	Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-31-23 07:00AM	Galera Announces Receipt of Type A Meeting Minutes and Strategic Update (GlobeNewswire) -54.02%
Sep-18-23 07:00AM	Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem (GlobeNewswire)
Sep-05-23 07:00AM	Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 12:00PM	All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy (Zacks)
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly) -7.19%
Aug-14-23 07:00AM	Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.89%
Aug-11-23 10:34AM	Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News (Zacks) -10.50%
Aug-10-23 10:12AM	Galera shares plunge 85% on FDA rejection; workforce cut by more than half (American City Business Journals) -83.93%
Aug-09-23 06:30PM	Galera shares tank after US FDA declines to approve inflammation disease drug (Reuters) +6.16%
04:31PM	Loading…
04:31PM	Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese (GlobeNewswire)
Jun-28-23 08:11AM	Despite Galera Therapeutics' Pullback, Insiders Still Gained US$102k (Simply Wall St.) +7.31%
Jun-05-23 02:15PM	Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting (GlobeNewswire)
May-18-23 08:45AM	Galera Therapeutics, Inc.'s (NASDAQ:GRTX) largest shareholders are retail investors with 45% ownership, institutions own 34% (Simply Wall St.) -7.38%
08:00AM	Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer (GlobeNewswire)
May-11-23 07:00AM	Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-04-23 04:01PM	Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-23 07:00AM	Galera Expands Commercial Leadership Team (GlobeNewswire) +8.24%
Apr-26-23 10:00AM	Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-10-23 07:00AM	Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology (GlobeNewswire)
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
07:00AM	Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates (GlobeNewswire)
Feb-15-23 12:43PM	Galera Therapeutics expects to raise $30M from direct stock offering (American City Business Journals) -15.74%
08:45AM	Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants (GlobeNewswire)
08:00AM	Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis (GlobeNewswire)
07:35AM	Loading…
Feb-05-23 07:35AM	Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky (Simply Wall St.)
Dec-12-22 11:37AM	Malvern-based Galera shares rise on FDA filing for lead cancer therapy drug (American City Business Journals)
07:00AM	Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis (GlobeNewswire)
Nov-22-22 07:00AM	Galera to Present at Piper Sandler Annual Healthcare Conference (GlobeNewswire)
Nov-09-22 07:00AM	Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-07-22 10:08AM	One Galera Therapeutics, Inc. (NASDAQ:GRTX) insider upped their stake by 50% in the previous year (Simply Wall St.)
Oct-26-22 03:16PM	Galera Therapeutics' Avasopasem Reduces Chemo-Related Kidney Disease By 50% Versus Placebo At One-Year (Benzinga) -5.62%
01:40PM	Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting (GlobeNewswire)
Sep-26-22 07:00AM	Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting (GlobeNewswire) +8.44%
Sep-06-22 07:00AM	Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +29.46%
Sep-01-22 07:00AM	Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (GlobeNewswire)
Aug-29-22 06:47AM	Here's Why Galera Therapeutics (NASDAQ:GRTX) Must Use Its Cash Wisely (Simply Wall St.)
Aug-09-22 07:00AM	Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates (GlobeNewswire)
Jun-29-22 12:05PM	Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation (Benzinga) -14.29%
07:30AM	Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC (GlobeNewswire)
Jun-02-22 07:00AM	Galera to Present at Jefferies Healthcare Conference (GlobeNewswire) +8.11%
May-30-22 11:11AM	Multiple insiders bought Galera Therapeutics, Inc. (NASDAQ:GRTX) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-26-22 05:00PM	Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem (GlobeNewswire)
May-16-22 02:25PM	Galera shares surge on news it will seek OK for lead drug candidate by year's end (American City Business Journals) +13.25%
07:30AM	Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates (GlobeNewswire)
07:00AM	Galera Announces Plan to Submit Avasopasem NDA by Year End (GlobeNewswire)
May-02-22 07:00AM	Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis (GlobeNewswire) +10.06%
Apr-27-22 10:00AM	Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.35%
Mar-21-22 06:34PM	Can Galera Therapeutics (NASDAQ:GRTX) Afford To Invest In Growth? (Simply Wall St.)
Mar-10-22 07:00AM	Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates (GlobeNewswire)
Jan-06-22 07:00AM	Galera to Present at H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-15-21 08:30AM	Are Options Traders Betting on a Big Move in Galera (GRTX) Stock? (Zacks) +7.41%
Dec-14-21 01:06PM	Galera shares double after firm announces 'corrected' study results for its lead drug candidate (American City Business Journals) +95.65%
11:31AM	GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today (InvestorPlace)
10:51AM	Why Galera Shares Are Surging More Than Double Today? (Benzinga)
07:00AM	Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem (GlobeNewswire)
05:22AM	Galera Therapeutics Surges After Corrected Trial Data (Investing.com)
Nov-16-21 09:08AM	Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer (Zacks)
Nov-15-21 07:00AM	Galera to Present at Two Upcoming Investor Conferences in November (GlobeNewswire)
Nov-10-21 07:00AM	Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-02-21 09:04AM	Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-28-21 07:23AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -17.01%
Oct-25-21 02:39PM	How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More (Benzinga)
Oct-21-21 12:00PM	All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy (Zacks) -5.63%
Oct-20-21 10:16AM	Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal (Zacks) -5.33%
Oct-19-21 12:11PM	Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge (Benzinga) -69.59%
07:00AM	Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis (GlobeNewswire)
Oct-15-21 08:23AM	What Type Of Shareholders Make Up Galera Therapeutics, Inc.'s (NASDAQ:GRTX) Share Registry? (Simply Wall St.)
Oct-12-21 07:00AM	Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer (GlobeNewswire)
Oct-05-21 02:52PM	Here's why local stocks are slightly underperforming the S&P 500 this year (American City Business Journals) +5.87%
Sep-14-21 07:00AM	Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer (GlobeNewswire)
Sep-08-21 07:00AM	Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters (GlobeNewswire)
Sep-07-21 07:00AM	Galera to Present at Three Upcoming Investor Conferences in September (GlobeNewswire)
Aug-16-21 08:01AM	Is Galera Therapeutics (NASDAQ:GRTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-10-21 07:00AM	Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments (GlobeNewswire)
Jun-28-21 07:00AM	Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis (GlobeNewswire)
Jun-03-21 04:00AM	Should You Take Comfort From Insider Transactions At Galera Therapeutics, Inc. (NASDAQ:GRTX)? (Simply Wall St.)
May-26-21 07:00AM	Galera to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-17-21 07:00AM	Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer (GlobeNewswire)
May-12-21 04:01PM	Science Translational Medicine Article Shows Galeras Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors (GlobeNewswire)
May-11-21 07:00AM	Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments (GlobeNewswire) +7.73%
May-05-21 07:00AM	Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference (GlobeNewswire) -6.62%
Apr-29-21 06:28AM	Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study (Benzinga) +22.84%
Apr-28-21 04:01PM	Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer (GlobeNewswire)
Mar-11-21 07:00AM	Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments (GlobeNewswire)
Mar-10-21 08:00AM	Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-19-21 02:39AM	We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-07-20 04:26PM	Is GRTX A Good Stock To Buy Now? (Insider Monkey)
Nov-20-20 08:00AM	Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-10-20 07:00AM	Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-20 08:00AM	Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference (GlobeNewswire) +19.45%
Oct-27-20 03:00PM	Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer (GlobeNewswire) -9.84%
Oct-23-20 05:00PM	Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer (GlobeNewswire)
Oct-22-20 08:00AM	Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-20-20 10:02AM	How Many Galera Therapeutics, Inc. (NASDAQ:GRTX) Shares Do Institutions Own? (Simply Wall St.)

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schneid Yair	10% Owner	Feb 08 '24	Buy	0.17	150,000	25,650	8,043,203	Feb 26 04:06 PM
Schneid Yair	10% Owner	Feb 07 '24	Buy	0.17	175,000	30,185	7,893,203	Feb 26 04:06 PM
Schneid Yair	10% Owner	Feb 06 '24	Buy	0.20	25,000	5,025	7,718,203	Feb 26 04:06 PM
Schneid Yair	10% Owner	Feb 05 '24	Buy	0.18	97,402	17,922	7,693,203	Feb 26 04:06 PM
Schneid Yair	10% Owner	Jan 30 '24	Buy	0.18	335,000	60,635	7,595,801	Feb 26 04:06 PM
Schneid Yair	10% Owner	Jan 29 '24	Buy	0.18	150,000	27,000	7,260,801	Feb 26 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRTX

Galera Therapeutics Inc

Upgrade your FINVIZ experience